Columbia University

Technology Ventures

Latest News

An experimental urine test that detects genetic changes associated with prostate cancer identified 92 percent of men with elevated PSA (prostate-specific antigen) levels who had high-grade cancers, according to a study published today in JAMA Oncology online.
Aclaris Therapeutics, Inc., a clinical stage specialty pharmaceutical company, today announced that it has entered into an agreement with the stockholders of Vixen Pharmaceuticals, Inc. to acquire all of the stock of Vixen.
Researchers from NewYork-Presbyterian/Columbia University Medical Center (CUMC) and University of Miami, with support from the National Institutes of Health and National Institute of Neurological Disorders and Stroke, co-authored a study that may help older people slow their rate of cognitive decline.
Four Columbia Engineering assistant professors have won Faculty Early Career Development (CAREER) awards from the National Science Foundation: Allison Bishop (Computer Science), Matei Ciocarlie, (Mechanical Engineering), Pierre Gentine (Earth and Environmental Engineering), and Nima Mesgarani (Electrical Engineering).
Alzheimer’s researchers at Columbia, speaking at a panel in March, are cautiously optimistic that effective treatments for Alzheimer’s are on the horizon.
Columbia Engineering is represented in five of the six winning research teams in the University’s annual Research Initiatives in Science and Engineering (RISE) competition.
Junfeng Yang, associate professor of computer science, is a very patient man but not when it comes to his Android phone. “Nobody likes sluggish mobile apps!” he exclaims.
While studying for his Ph.D. in electrical engineering at Columbia University six or seven years ago, Marshall Cox regulated his room’s temperature in winter the way most New Yorkers with steam radiators do.
Sometimes, to make progress, you have to get your hands dirty. Professor Kartik Chandran and his research group in Columbia’s Department of Environmental Engineering are getting their hands extra dirty.
Bacteria have developed their own “force” to hide from our antibiotics, and they are increasingly using this strategy to chip away at the effectiveness of polymyxins, our last line of defense against some “superbug” infections.